Trials / Terminated
TerminatedNCT00223041
Cranoc Lipid Study in Renal Transplantation
Cardiovascular Events in Renal Transplant Recipients With Low LDL-cholesterol Receiving Tacrolimus in Combination With the Statin Fluvastatin
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital Schleswig-Holstein · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (\<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.
Detailed description
Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (\<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluvastatin | Arm A receives fluvastatin Arm b receives no fluvastatin |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2009-11-01
- Completion
- 2010-12-01
- First posted
- 2005-09-22
- Last updated
- 2011-08-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00223041. Inclusion in this directory is not an endorsement.